ClinicalTrials.gg
CompletedNCT05262569Updated Aug 9, 2022

Postoperative Opioid Use and Ileus Occurrence---A Case Control Study

An observational study in Ileus and Opioid Use, sponsored by Peking University People's Hospital. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-09.

Sponsored by Peking University People's Hospital · Observational

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
596
Ages
18 Years and older
Sex
All
01

Study summary

Postoperative ileus (POI) is a significant complication after colorectal surgery, with reported incidence ranging from 10\~30%, leading to increased morbidity, hospital length of stay, and thus medical cost. To determine the risk factors for POI is one of the key elements for Enhanced Recovery after Surgery protocol. Increased perioperative opioid usage has been proposed as an independent risk factor for postoperative ileus, as perioperative opioid minimization has proposed to be an effective measure to decrease the incidence of POI. Although opioids are widely used to attenuate stress during surgery, and represent the cornerstone of pain treatment, anesthesiologists are strive to minimize opioid use to decrease opioid-related GI side effects. In this study, the investigators aim to find out the general occurrence of POI in the laparoscopic colorectal surgery and the effects of the postoperative opioid usage on this outcome. The strategies of opioid minimization was also investigated.

Read the detailed description

2.1 Study design For this case-control study, all elective laparoscopic colorectal procedures performed at a university hospital between Jan 2018 and June 2020 were retrospectively collected by reviewing the institutional colorectal surgery database. The study protocol was approved by the Institutional Review Board of Peking University People's Hospital (2021PHB144-001, May 24, 2021), Beijing, China, and informed consent was waived due to the retrospective design.

The anesthesia medical information system was searched for patients aged 18 years old and above, undergoing elective laparoscopic colorectal procedures who received patient controlled intravenous analgesia postoperatively. Patients were excluded if they had chronic opioid use, converted to open, admitted to intensive care unit(ICU), patient controlled analgesia (PCA) regimens other than sufentanil, PCA used shorter than 48 hours, or incomplete postoperative opioid usage record. Patients were followed up until discharge from the hospital.

2.2 Patient allocation Patients who experienced postoperative ileus were included in ileus group. In accordance with the definition of Vather et al, diagnosis of postoperative ileus required 2 or more of following persistent symptoms on the fourth postoperative day and onward: nausea and vomiting, inability to tolerate solid or semi-liquid diet or failure to pass gas or stool during a 24 hour period, abdominal distension and radiological evidence of ileus. Patient charts, including radiographs were evaluated retrospectively. Diagnosis of an ileus was confirmed clinically and radiographically in all cases. The control group (at a 1:1 ratio) was matched by selecting the same range of age (±5 years of age), the same grade of American Society of Anesthesiology(ASA) classification, and the same types of surgery (colectomy, rectectomy, whole colon resection, or others).

2.3 Perioperative management All patients received standard anesthesia protocol for laparoscopic colorectal procedures within Peking University People's Hospital. Patients might received bilateral transversus abdominis plane(TAP) blocks (0.3% Ropivacaine of 30\~40ml under the ultrasound guidance) at the discretion of the anesthesiologist in charge.

General anesthesia was induced using etomidate (0.2-0.6 mg/kg) and sufentanil (0.3 μg/kg) and maintained with continuous infusion of propofol (4-6 mg/kg/h) to target a bispectral index of 40-60. Cisatracurium (0.15 mg/kg) was injected intravenously to facilitate endotracheal intubation. Intravenous sufentanil (0.1 μg/kg) was added before skin incision. During surgery, continuous infusion of remifentanil (0.1-0.2 μg /kg/min) was adjusted to keep heart rate (HR) and mean arterial blood pressure (MAP) within 80-120% of baseline. Hypotension (MAP \< 80% of baseline) lasting for 3 min was managed with a bolus of 6 mg of ephedrine or 50 μg of phenylephrine. Bradycardia (HR \< 45/min) was treated with atropine (0.25-0.5 mg). At the end of surgery, neostigmine (1 mg) and atropine (0.5 mg) were used to antagonize neuromuscular blockade, and tracheal extubation was performed when the patient was fully awake and breathing adequately. Patients were transferred to the post-anesthesia care unit (PACU) and discharged when the Modified Aldrete Score reached 10.

2.4 Postoperative pain management Postoperative pain management was charged by the acute pain service(APS). Acute pain or side effects related to the opioid was managed through the setting of intravenous patient-controlled analgesia(PCA) device. Patients received intravenous, intramuscular or oral analgesic rescue only after the PCA withdrawal.

In general, a patient-controlled analgesia (PCA) device was attached after tracheal extubation. The PCA was set to provide a bolus of 2\~3μg sufentanil (1 μg/ml) with a lockout time of 10\~15 min with or without basal infusion, 2\~3ml/h (sufentanil 1μg/ml), which was set at the discretion of the anesthesiologist in charge according to the patient's age and weight. After surgery, pain score was verbally rated using the 11-point numeric rating scale (NRS), on which 0 indicates no pain and 10 indicates worst imaginable pain. Patients could self-administer intravenous sufentanil bolus via PCA (2\~3μg, 1 μg/ml) postoperatively as rescue analgesia when the NRS score was ≥4, or as needed. PCA was maintained for at least the first 48 h after surgery.

2.5 Study outcomes and measurements Multiple potential risk factors for POI were considered based on literature review. Baseline factors included age(matched), gender, BMI, presence of major comorbidities (cardiovascular diseases, cerebral diseases, pulmonary diseases, or diabetes), ASA classification (matched), and previous abdominal surgery. Operative factors included type of surgery(matched), length of the surgery, estimated blood loss, total input, time to pass stool in patients' without enterostomy, time to tolerance of oral diet, and postoperative length of hospital stay. Analgesia related risk factors included TAP block, intra-operative opioid use(converted into equivalent doses of morphine, mg/kg), postoperative day 1 (POD1) and total post-operative opioid (Sufentanil, μg/kg), and PCA setting (with or without basal infusion). Postoperative NRS at rest and when coughing were recorded. Adverse events occurring prior to discharge were also collected from the hospital chart.

2.6 Statistical analysis Statistical analysis was performed using the SPSS statistical software package (SPSS Inc., Chicago, IL). Continuous variables are expressed as mean ± standard deviation(SD) or medians with interquartile range and categorical variables as numbers and percentages. Between-group differences were evaluated using the independent t test or Mann-Whitney U test for continuous variables and the χ2 test or Fisher exact test for categorical variables, as appropriate.

02

Conditions studied

  • Ileus
  • Opioid Use

Browse trials for

Keywords

  • ileus
  • opioid use
  • enhanced recovery after surgery
  • colorectal surgery
03

In context

Ileus

167 studies on the registry are indexed under Ileus; 23 are open to participants now.

This study's enrollment of 596 is above the median of 159 across 26 observational studies indexed under Ileus.

Browse Ileus studies →

Lead sponsor

Peking University People's Hospital is the lead sponsor of 609 studies on the registry; 247 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All elective laparoscopic colorectal procedures performed at a university hospital between Jan 2018 and June 2020 were retrospectively collected by reviewing the institutional colorectal surgery database.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years old and above
  • Underwent elective laparoscopic colorectal procedures
  • Received patient controlled intravenous analgesia postoperatively

Exclusion criteria

Exclusion Criteria:

  • Chronic opioid use
  • Converted to open
  • Admitted to ICU
  • PCA regimens other than sufentanil
  • PCA used shorter than 48 hours
  • Incomplete postoperative opioid usage record
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
596 participants (actual)
Patient registry
No

Groups and cohorts

  • ileus group

    Patients developed postoperative ileus

    Other: ileus

  • control group

    Patients did not develop postoperative ileus

Interventions

  • Otherileus

    retrospectively allocation according to a postoperative outcome-ileus

06

What researchers measure

Primary outcomes

  1. postoperative opioid usage

    Sufentanil(μg/kg) used through patient-controlled analgesia

    Time frame: Within 3 postoperative days

Secondary outcomes

  1. Use of transversus abdominis plane(TAP) block

    The percentage TAP block of each group

    Time frame: Before surgery

  2. Patent-controlled analgesia(PCA) setting

    The percentage of PCA setting with basal infusion

    Time frame: Within 3 postoperative days

07

Study locations

1 site
  • Peking University People's Hospital
    Beijing, Beijing 100044, China
08

References and documents

Publications

  • Wu CL, King AB, Geiger TM, Grant MC, Grocott MPW, Gupta R, Hah JM, Miller TE, Shaw AD, Gan TJ, Thacker JKM, Mythen MG, McEvoy MD; Fourth Perioperative Quality Initiative Workgroup. American Society for Enhanced Recovery and Perioperative Quality Initiative Joint Consensus Statement on Perioperative Opioid Minimization in Opioid-Naive Patients. Anesth Analg. 2019 Aug;129(2):567-577. doi: 10.1213/ANE.0000000000004194. PubMed 31082966 ↗
  • Artinyan A, Nunoo-Mensah JW, Balasubramaniam S, Gauderman J, Essani R, Gonzalez-Ruiz C, Kaiser AM, Beart RW Jr. Prolonged postoperative ileus-definition, risk factors, and predictors after surgery. World J Surg. 2008 Jul;32(7):1495-500. doi: 10.1007/s00268-008-9491-2. PubMed 18305994 ↗
  • Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001 Nov;182(5A Suppl):11S-18S. doi: 10.1016/s0002-9610(01)00782-6. PubMed 11755892 ↗
  • Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol. 2011 May;106(5):835-42; quiz 843. doi: 10.1038/ajg.2011.30. Epub 2011 Feb 22. PubMed 21343919 ↗
  • Ahn JH, Ahn HJ. Effect of thoracic epidural analgesia on recovery of bowel function after major upper abdominal surgery. J Clin Anesth. 2016 Nov;34:247-52. doi: 10.1016/j.jclinane.2016.04.042. Epub 2016 May 13. PubMed 27687384 ↗
  • Stokes AL, Adhikary SD, Quintili A, Puleo FJ, Choi CS, Hollenbeak CS, Messaris E. Liposomal Bupivacaine Use in Transversus Abdominis Plane Blocks Reduces Pain and Postoperative Intravenous Opioid Requirement After Colorectal Surgery. Dis Colon Rectum. 2017 Feb;60(2):170-177. doi: 10.1097/DCR.0000000000000747. PubMed 28059913 ↗
  • Fields AC, Weiner SG, Maldonado LJ, Cavallaro PM, Melnitchouk N, Goldberg J, Stopfkuchen-Evans MF, Baker O, Bordeianou LG, Bleday R. Implementation of liposomal bupivacaine transversus abdominis plane blocks into the colorectal enhanced recovery after surgery protocol: a natural experiment. Int J Colorectal Dis. 2020 Jan;35(1):133-138. doi: 10.1007/s00384-019-03457-1. Epub 2019 Dec 4. PubMed 31797098 ↗
  • Pedrazzani C, Menestrina N, Moro M, Brazzo G, Mantovani G, Polati E, Guglielmi A. Local wound infiltration plus transversus abdominis plane (TAP) block versus local wound infiltration in laparoscopic colorectal surgery and ERAS program. Surg Endosc. 2016 Nov;30(11):5117-5125. doi: 10.1007/s00464-016-4862-5. Epub 2016 Mar 22. PubMed 27005290 ↗
  • Chen JY, Ko TL, Wen YR, Wu SC, Chou YH, Yien HW, Kuo CD. Opioid-sparing effects of ketorolac and its correlation with the recovery of postoperative bowel function in colorectal surgery patients: a prospective randomized double-blinded study. Clin J Pain. 2009 Jul-Aug;25(6):485-9. doi: 10.1097/AJP.0b013e31819a506b. PubMed 19542795 ↗
  • Aryaie AH, Lalezari S, Sergent WK, Puckett Y, Juergens C, Ratermann C, Ogg C. Decreased opioid consumption and enhance recovery with the addition of IV Acetaminophen in colorectal patients: a prospective, multi-institutional, randomized, double-blinded, placebo-controlled study (DOCIVA study). Surg Endosc. 2018 Aug;32(8):3432-3438. doi: 10.1007/s00464-018-6062-y. Epub 2018 Jan 19. PubMed 29352454 ↗
  • Jung H, Lee KH, Jeong Y, Lee KH, Yoon S, Kim WH, Lee HJ. Effect of Fentanyl-Based Intravenous Patient-Controlled Analgesia with and without Basal Infusion on Postoperative Opioid Consumption and Opioid-Related Side Effects: A Retrospective Cohort Study. J Pain Res. 2020 Nov 24;13:3095-3106. doi: 10.2147/JPR.S281041. eCollection 2020. PubMed 33262644 ↗
  • Vather R, Josephson R, Jaung R, Robertson J, Bissett I. Development of a risk stratification system for the occurrence of prolonged postoperative ileus after colorectal surgery: a prospective risk factor analysis. Surgery. 2015 Apr;157(4):764-73. doi: 10.1016/j.surg.2014.12.005. Epub 2015 Feb 25. PubMed 25724094 ↗
  • Vather R, Bissett IP. Risk factors for the development of prolonged post-operative ileus following elective colorectal surgery. Int J Colorectal Dis. 2013 Oct;28(10):1385-91. doi: 10.1007/s00384-013-1704-y. Epub 2013 May 21. PubMed 23689489 ↗
  • Grass F, Slieker J, Jurt J, Kummer A, Sola J, Hahnloser D, Demartines N, Hubner M. Postoperative ileus in an enhanced recovery pathway-a retrospective cohort study. Int J Colorectal Dis. 2017 May;32(5):675-681. doi: 10.1007/s00384-017-2789-5. Epub 2017 Mar 11. PubMed 28285365 ↗
  • Yuan L, O'Grady G, Milne T, Jaung R, Vather R, Bissett IP. Prospective comparison of return of bowel function after left versus right colectomy. ANZ J Surg. 2018 Apr;88(4):E242-E247. doi: 10.1111/ans.13823. Epub 2016 Nov 2. PubMed 27806440 ↗
  • Kim IK, Kang J, Baik SH, Lee KY, Kim NK, Sohn SK. Impact of prior abdominal surgery on postoperative prolonged ileus after ileostomy repair. Asian J Surg. 2018 Jan;41(1):86-91. doi: 10.1016/j.asjsur.2016.07.006. Epub 2016 Aug 17. PubMed 27542335 ↗
  • Walter CJ, Maxwell-Armstrong C, Pinkney TD, Conaghan PJ, Bedforth N, Gornall CB, Acheson AG. A randomised controlled trial of the efficacy of ultrasound-guided transversus abdominis plane (TAP) block in laparoscopic colorectal surgery. Surg Endosc. 2013 Jul;27(7):2366-72. doi: 10.1007/s00464-013-2791-0. Epub 2013 Feb 7. PubMed 23389068 ↗
  • Gustafsson UO, Scott MJ, Hubner M, Nygren J, Demartines N, Francis N, Rockall TA, Young-Fadok TM, Hill AG, Soop M, de Boer HD, Urman RD, Chang GJ, Fichera A, Kessler H, Grass F, Whang EE, Fawcett WJ, Carli F, Lobo DN, Rollins KE, Balfour A, Baldini G, Riedel B, Ljungqvist O. Guidelines for Perioperative Care in Elective Colorectal Surgery: Enhanced Recovery After Surgery (ERAS(R)) Society Recommendations: 2018. World J Surg. 2019 Mar;43(3):659-695. doi: 10.1007/s00268-018-4844-y. PubMed 30426190 ↗
  • Zhen L, Li X, Gao X, Wei H, Lei X. Dose determination of sufentanil for intravenous patient-controlled analgesia with background infusion in abdominal surgeries: A random study. PLoS One. 2018 Oct 17;13(10):e0205959. doi: 10.1371/journal.pone.0205959. eCollection 2018. PubMed 30332482 ↗

Individual participant data

Plan to share: Undecided — It need to be discussed within the study group when the results are clear.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05262569
Responsible party
Juhui (Assistant professor, Peking University People's Hospital) — Principal investigator
First posted
Mar 2, 2022
Start date
Apr 1, 2022
Primary completion
May 31, 2022
Completion
Jun 30, 2022
Last update
Aug 9, 2022

Study contacts

Juhui, Dr.
principal investigator · Peking University People's Hospital, Beijing, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion